Upstream Bio (UPB) Stock Price, News & Analysis

Company Overview

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages. In the immuno-oncology sphere, Upstream Bio is exploring therapeutic vaccine constructs designed to activate tumor-specific T cells, while its infectious disease programs seek to induce protective immunity against viral pathogens. By integrating translational biomarkers and adaptive clinical trial designs, the company strives to accelerate candidate selection and optimize dosing regimens.

Upstream Bio operates research facilities in the United States and collaborates with academic and industry partners across several regions to advance its programs globally. The company’s leadership team comprises seasoned executives and scientists with deep expertise in virology, vaccine development and regulatory affairs. Upstream Bio is listed on the Nasdaq Global Market under the symbol UPB and continues to build strategic alliances aimed at expanding its pipeline and commercial capabilities.

Key Stats

• Today's Range: $8.88 to $9.50
• 50-Day Range: $7.36 to $10.49
• 52-Week Range: $7.25 to $33.68
• Volume: 262,659 shs
• Average Volume: 551,511 shs
• Market Capitalization: $496.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.00
• Consensus Rating: Moderate Buy

Upstream Bio Stock Analysis - MarketRank™

Upstream Bio scored higher than 37% of companies evaluated by MarketBeat, and ranked 643rd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Upstream Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Upstream Bio has a consensus price target of $39.00, representing about 327.6% upside from its current price of $9.12.

Amount of Analyst Coverage

Upstream Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Upstream Bio are expected to decrease in the coming year, from ($3.02) to ($3.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Upstream Bio is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Upstream Bio is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Upstream Bio has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for UPB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Upstream Bio does not currently pay a dividend.

Dividend Growth

Upstream Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 1.18

News Sentiment

Upstream Bio has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Upstream Bio this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for UPB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Upstream Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,915.00 in company stock.

Percentage Held by Insiders

13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Upstream Bio has minimal institutional ownership at this time.

UPB Stock Analysis - Frequently Asked Questions

How have UPB shares performed this year?

Upstream Bio's stock was trading at $27.15 on January 1st, 2026. Since then, UPB stock has decreased by 66.4% and is now trading at $9.12.

How were Upstream Bio's earnings last quarter?

Upstream Bio, Inc. (NASDAQ:UPB) announced its earnings results on Thursday, March, 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by $0.06. The firm had revenue of $0.67 million for the quarter, compared to analysts' expectations of $0.52 million. Upstream Bio had a negative net margin of 5,026.03% and a negative trailing twelve-month return on equity of 36.48%.

When did Upstream Bio IPO?

Upstream Bio (UPB) raised $200 million in an IPO on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO.

Who are Upstream Bio's major shareholders?

Top institutional shareholders of Upstream Bio include Y Intercept Hong Kong Ltd (1.84%), Pictet Asset Management Holding SA (1.35%), Hsbc Holdings PLC (1.18%) and Bank of New York Mellon Corp (0.15%). Insiders that own company stock include Erez Chimovits, Ai Upstream Llc and Michael Gray.
View institutional ownership trends.

How do I buy shares of Upstream Bio?

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 3/26/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:UPB
• Previous Symbol: NASDAQ:UPB
• CIK: 2022626
• Web: upstreambio.com
• Phone: (781) 208-2466
• Fax: N/A
• Employees: 38
• Year Founded: 2021

Price Target and Rating

• Average Price Target for Upstream Bio: $39.00
• High Price Target: $51.00
• Low Price Target: $15.00
• Potential Upside/Downside: +327.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$143.44 million
• Net Margins: -5,026.03%
• Pretax Margin: -5,026.03%
• Return on Equity: -36.48%
• Return on Assets: -35.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.15
• Quick Ratio: 26.15

Sales & Book Value

• Annual Sales: $2.85 million
• Price / Sales: 174.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.29 per share
• Price / Book: 1.45

Miscellaneous

• Outstanding Shares: 54,420,000
• Free Float: 47,041,000
• Market Cap: $496.31 million
• Optionable: N/A
• Beta: 1.28